Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

691 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B. Ruszniewski P, et al. Among authors: de herder ww. Neuroendocrinology. 2004;80(4):244-51. doi: 10.1159/000082875. Epub 2004 Dec 22. Neuroendocrinology. 2004. PMID: 15627802 Clinical Trial.
Well-differentiated pancreatic tumor/carcinoma: insulinoma.
de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D; Frascati Consensus Conference; European Neuroendocrine Tumor Society. de Herder WW, et al. Neuroendocrinology. 2006;84(3):183-8. doi: 10.1159/000098010. Epub 2007 Feb 20. Neuroendocrinology. 2006. PMID: 17312378 Free article. No abstract available.
Rare functioning pancreatic endocrine tumors.
O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B; Frascati Consensus Conference; European Neuroendocrine Tumor Society. O'Toole D, et al. Among authors: de herder ww. Neuroendocrinology. 2006;84(3):189-95. doi: 10.1159/000098011. Epub 2007 Feb 20. Neuroendocrinology. 2006. PMID: 17312379 Free article. No abstract available.
Gastroenteropancreatic neuroendocrine tumours.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Modlin IM, et al. Among authors: de herder ww. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Lancet Oncol. 2008. PMID: 18177818 Review.
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants. Jensen RT, et al. Among authors: de herder ww. Neuroendocrinology. 2012;95(2):98-119. doi: 10.1159/000335591. Epub 2012 Feb 15. Neuroendocrinology. 2012. PMID: 22261919 Free PMC article. No abstract available.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Kvols LK, et al. Among authors: de herder ww. Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct. Endocr Relat Cancer. 2012. PMID: 22807497 Clinical Trial.
691 results